AFP and hepatocellular carcinoma: Among HCC cases, 55% in the training set and 51% in the validation set were diagnosed at BCLC stage 0 and A, while patients with relatively low AFP levels (< 20 ng/mL) accounted for 47.8% and 40.8% in the two sets.